Injective now handles $3.57 billion in daily trading volume for tokenized equities. That figure, disclosed by the platform this week, places it at the center of a fast-growing market where traditional stocks trade on blockchain rails. The volume comes as regulators in multiple jurisdictions signal they may revisit rules around onchain securities.
Tokenized Equities and the Promise of Global Access
Tokenized equities are digital representations of stocks—Apple, Tesla, or a broad ETF—that trade 24/7 on decentralized networks. Injective's model lets users buy fractional shares without a brokerage account or a minimum deposit. The pitch is straight: anyone with an internet connection can access U.S. equities, bypassing the gatekeepers that keep many retail investors out.
That approach has found traction. The $3.57 billion figure represents not just spot trading but also swaps, lending, and derivatives built on those tokens. It's a number that rivals the daily volume of some mid-tier national stock exchanges.
But the growth is not just about convenience. Injective and similar platforms argue that moving equities onchain cuts settlement times from two days to seconds, reduces counterparty risk, and opens up new strategies like atomic swaps between stocks and crypto.
Regulatory Crosscurrents
The same features that attract users also attract scrutiny. Securities laws in the U.S. and Europe were written for a world where stocks are held by a central depository and traded on regulated exchanges. Tokenized equities blur those lines.
Several regulators are now taking a fresh look. The SEC has not issued specific guidance on tokenized stocks, but its enforcement cases against crypto lending products suggest it views many onchain tokens as securities. Meanwhile, the European Securities and Markets Authority is piloting a DLT pilot regime that could grant exemptions for tokenized instruments. In Asia, Hong Kong and Singapore have both signaled they may create new licensing categories for platforms handling digital securities.
The upshot: the operational landscape for tokenized equities may look very different a year from now. A clear regulatory framework could unlock institutional money. A patchwork of bans and restrictions could push volume back into gray markets.
What’s Next for Onchain Securities
Injective's volume shows demand is real. But the platform operates without explicit permission from any major securities regulator. That status quo can't last forever.
The next real test comes when the ESMA's DLT pilot regime publishes its first set of approved platforms, expected in the coming months. If Injective or a competitor gets a green light there, it could set a precedent for how tokenized equities are supervised globally. If not, the gap between regulatory intent and onchain reality will only widen.
